GLUE vs LLY vs VRTX vs CRL vs IQV

For growth investors, Monte Rosa Therapeutics, Inc.

(GLUE) is the stronger pick with 63. 5% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). IQVIA Holdings Inc. (IQV) offers the better valuation at 23. 1x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 23. 1x versus Eli Lilly and Company at 49. 4x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Vertex Pharmaceuticals Incorporated's 2. 78x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -47. 2% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: LLY returned +1485% versus GLUE's -13. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

53β versus Charles River Laboratories International, Inc. 's 1. 39β — meaning CRL is approximately 162% more volatile than LLY relative to the S&P 500. On balance sheet safety, Monte Rosa Therapeutics, Inc. (GLUE) carries a lower debt/equity ratio of 17% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Monte Rosa Therapeutics, Inc.

(GLUE) is pulling ahead at 63. 5% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -31. 2% for Monte Rosa Therapeutics, Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -43. 8% for GLUE. At the gross margin level — before operating expenses — GLUE leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Vertex Pharmaceuticals Incorporated's 2. 78x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 30. 9x for Eli Lilly and Company — 16. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GLUE: 74. 1% to $31. 75.

In this comparison, LLY (0.

5% yield) pays a dividend. GLUE, VRTX, CRL, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Both have compounded well over 10 years (LLY: +1485%, GLUE: -13. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLUE is a small-cap high-growth stock; LLY is a mega-cap high-growth stock; VRTX is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. LLY pays a dividend while GLUE, VRTX, CRL, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.